. Author manuscript; available in PMC: 2016 Jul 1.

Published in final edited form as: Nat Rev Rheumatol. 2015 Dec 10;12(1):49–62. doi: 10.1038/nrrheum.2015.169

Table 1.

TNF inhibitors and approved indications

Drug	Description	Indications
Monoclonal antibodies
Infliximab	Chimeric (mouse and human) whole mAb against TNF	Crohn disease (adult and paediatric), ulcerative colitis (adult and paediatric), RA, PsA, plaque psoriasis, AS
Adalimumab	Human whole mAb against TNF	RA, ulcerative colitis, Crohn disease, plaque psoriasis, PsA, AS, JIA (paediatric), hidradenitis suppurativa
Certolizumab pegol	Humanized PEGylated Fab fragment of a mAb against TNF	RA, PsA, AS, Crohn's disease
Golimumab	Human whole mAb against TNF	RA, PsA, AS, ulcerative colitis
Soluble TNFR
Etanercept	TNFR2 fused to IgG1 Fc	RA, plaque psoriasis, PsA, AS, JIA

Indications are for adult patients unless noted otherwise. AS, ankylosing spondylitis; JIA, juvenile idiopathic arthritis; mAb, monoclonal antibody; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNFR, TNF receptor.